Gi Division News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Entero Therapeutics Presents Two Posters on Celiac Disease Research at the 2024 Digestive Disease Week (DDW) Conference

Entero Therapeutics Presents Two Posters on Celiac Disease Research at the 2024 Digestive Disease Week (DDW) Conference
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Boca ratonUnited statesJack syageJames sapirsteinJennifer sealy voyksnerLiz phillipsDrug administrationFirst wave bio incSociety for surgery of the alimentary tractExchange commissionGi divisionAmerican society for gastrointestinal endoscopyAmerican gastroenterological associationEntero therapeutics incCompany annual report on formTherapeutics presents two posters

First Wave BioPharma (FWBI) CEO Issues Letter to Stockholders, Provides 2024 Outlook

First Wave BioPharma (FWBI) CEO Issues Letter to Stockholders, Provides 2024 Outlook
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesChaitan khoslaJames sapirsteinJack syageStanford universityFirst wave biopharma incDrug administrationGi divisionFirst wave biopharmaStrategic rationaleOperational fitAnticipated business combinationChief operating officerProfessor chaitan khoslaStrategic pharma commercial agreementInstitutional investment anticipated

First Wave BioPharma Chairman and CEO Issues Letter to Shareholders Highlighting Recent Accomplishments and Outlook for 2024

First Wave BioPharma Chairman and CEO Issues Letter to Shareholders Highlighting Recent Accomplishments and Outlook for 2024
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Boca ratonUnited statesJack syageDavid schemeliaChaitan khoslaJames sapirsteinFirst wave biopharma incTiberend strategic advisors incDrug administrationGi divisionExchange commissionCompany annual report on formStanford universityFirst wave bio incWave biopharmaFirst wave biopharma

First Wave BioPharma Announces Entry into Term Sheet for Business Combination with ImmunogenX Establishing a Leading Late-Stage GI-Focused Biopharmaceutical Company

Phase 3-ready latiglutenase, a targeted oral biotherapeutic for celiac disease, will expand First Wave BioPharma’s late-stage gastrointestinal disease clinical pipeline A concurrent institutional.

Boca ratonUnited statesJames sapirsteinChaitan khoslaJack syageDavid schemeliaCompany annual report on formDrug administrationFirst wave biopharma incFirst wave bio incTungsten partnersFinalis securitiesImmunogenx incTiberend strategic advisors incStanford universityExchange commission

First Wave BioPharma To Acquire ImmunogenX To Bolster Gastrointestinal-Focused Pipeline - First Wave BioPharma (NASDAQ:FWBI)

First Wave BioPharma Inc (NASDAQ: FWBI) has signed a non-binding term sheet to acquire ImmunogenX in an all-stock transaction with the combined company focused on advancing a pipeline for gastrointestinal (GI) diseases.

James sapirsteinJack syageBiopharma incGi divisionFirst wave biopharmaChief medicalWave biopharmaFirst wave